# A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

> **NCT04564066** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 54 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** efgartigimod IV
- **BIOLOGICAL:** efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT04564066
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-18
- **Primary completion:** 2020-12-24
- **Final completion:** 2021-02-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564066, "A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04564066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*